Fortress Biotech, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Asset Purchase Agreements (Narrative) (Details)

Asset Purchase Agreements (Narrative) (Details) $ in Thousands					1 Months Ended			3 Months Ended	12 Months Ended		24 Months Ended
	Jul. 28, 2023 USD ($)	Apr. 21, 2023 USD ($)	Oct. 11, 2022 USD ($)	Feb. 24, 2021 USD ($)	Dec. 31, 2023 USD ($) D	Nov. 30, 2023 USD ($)	Oct. 31, 2023 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2023 USD ($)	Jul. 31, 2022 USD ($)
Proceeds from Issuance of Common Stock									$ 2,041	$ 6,053
Payments of milestones											$ 500
Collaboration revenue									5,229	1,882
Sale of Stock, Consideration Received on Transaction						$ 8,900	$ 10,000
Asset purchase agreement to acquire Aevitas proprietary rights
Fair value of Aevitas interest retained		$ 2,600
Cyprium \| Sentnyl
Contingent liability					$ 4,500				4,500		4,500
Upfront fees payment				$ 8,000	8,000
Collaboration revenue									700	$ 1,900
Avenue
Proceeds from Issuance of Common Stock			$ 10,300			$ 5,000
Avenue \| InvaGen
Percentage of contingent fee payable												7.50%
Contingent fee payable from proceeds of future financing												$ 4,000
Aevitas
Loss from deconsolidation of Aevitas									3,400
Aevitas \| Maximum \| Asset purchase agreement to acquire Aevitas proprietary rights
Upfront payment to be paid		$ 140,000
Mustang
Expenses under manufacturing services agreement								$ 4,100
Asset acquisition, minimum commitment amount	$ 8,000
Manufacturing services in excess of the minimum commitment	$ 3,000
Asset acquisition, minimum commitment amount payment, term	2 years
Asset acquisition, minimum commitment amount paid, percentage	25.00%
Mustang \| Manufacturing Services Agreement [Member]
Reimbursed costs								2,400
Receivable					$ 3,200				3,200		3,200
Mustang \| UBriGene
Consideration Transferred	$ 6,000
Contingent liability	$ 5,000
Contingent consideration period	2 years
Contingent liability, Issuance of equity securities	$ 10,000
Contingent consideration, Proposed lease period	2 years
Loss on sale of asset								$ 1,500
Transaction Related Expenses	$ 300
SPMA \| Cyprium \| Sentnyl \| Manufacturing Services Agreement [Member]
Number of days to assume control over development of CUTX-101 in the event that CUTX-101 NDA approval has not been obtained \| D					45
FDA approval of the NDA \| Cyprium \| Sentnyl \| Maximum
Payments of milestones				$ 129,000
Annual net sales up to $75 million \| Cyprium \| Sentynl APA
Contingent liability					$ 75,000				75,000		75,000
Royalty on net sales to be received (in percent)					3.00%
Annual net sales between $75 million and $100 million \| Cyprium \| Sentynl APA
Consideration Transferred					$ 100,000
Contingent liability					$ 75,000				$ 75,000		$ 75,000
Royalty on net sales to be received (in percent)					8.75%
Annual net sales in excess of $100 million \| Cyprium \| Sentynl APA
Consideration Transferred					$ 100,000
Royalty on net sales to be received (in percent)					12.50%